Table 2:
Major Adverse Cardiovascular Event and Major Bleeding Event Rates by Heart Failure Status among Individuals Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndromes in the Pharmacogenomic Resource to improve Medication Effectiveness Genotype Guided Antiplatelet Therapy Cohort, April 2014 – November 2019.
| Heart Failure | IRR (95% CI) | Model 1 HR (95% CI)1 | Model 2 HR (95% CI)2 | ||||
|---|---|---|---|---|---|---|---|
| Yes (n=370) | No (n=775) | ||||||
| Follow-up (years) | 264.96 | 627.54 | |||||
| N | Incidence rate* | N | Incidence rate* | ||||
| MACE | 126 | 47.8 | 150 | 23.9 | 1.99 (1.57-2.52) | 1.44 (1.11-1.86) | 1.31 (1.00-1.72) |
| All-Cause Mortality | 43 | 16.2 | 37 | 5.9 | 2.75 (1.77-4.27) | 1.93 (1.19-3.13) | 1.76 (1.04-2.99) |
| Non-Fatal Myocardial Infarction | 82 | 31.0 | 99 | 15.8 | 1.96 (1.46-2.63) | 1.39 (1.01-1.90) | 1.29 (0.93-1.81) |
| Non-Fatal Ischemic Stroke/TIA | 9 | 3.4 | 20 | 3.2 | 1.07 (0.49-2.34) | ||
| Stent Thrombosis | 8 | 3.0 | 11 | 1.8 | 1.72 (0.69-4.28) | ||
| Major Bleeds | 58 | 21.9 | 70 | 11.2 | 1.96 (1.39-2.78) | 1.73 (1.89-2.52) | 1.29 (0.86-1.93) |
| Intracranial | 3 | 1.1 | 5 | 0.8 | 1.42 (0.34-5.95) | ||
| Gastrointestinal | 25 | 9.4 | 27 | 4.3 | 2.19 (1.27-3.78) | 2.06 (1.14-3.73) | 1.70 (0.89-3.26) |
| Other | 30 | 11.3 | 38 | 6.1 | 1.87 (1.16-3.02) | 1.60 (0.95-2.68) | 1.17 (0.68-2.03) |
Incidence rate per 100 patient years.
Abbreviations: CHF, congestive heart failure; CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; MACE, major adverse cardiovascular event; N, number; TIA, transient ischemic attack.
Adjusted for age, female sex, black race, hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, end-stage renal disease, peripheral vascular disease, insurance status, and alcohol use.
Adjusted for covariates included in model 1 plus the following medications prescribed at discharge: DAPT (dual-antiplatelet therapy), calcium-channel blockers, aldosterone inhibitors, diuretics, or anticoagulation (warfarin or apixaban).